Current gene-mapping strategies in experimental models of multiple sclerosis

Scandinavian Journal of Immunology

Volumn 60, Issue 1, 2004, Pages 39-51

  Becanovic, K ^a   Jagodic, M ^a   Wallstrom E ^a   Olsson, T ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKOCYTE ANTIGEN;

ACCURACY; ALLELE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; ENCEPHALOMYELITIS; EXPERIMENTAL TEST; GENE; GENE CONTROL; GENE ISOLATION; GENE LOCUS; GENE MAPPING; GENETIC ANALYSIS; GENETIC EPISTASIS; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; LEUKOCYTE ANTIGEN GENE; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROMORPHOLOGY; MOLECULAR EVOLUTION; MULTIPLE SCLEROSIS; PATHOGENESIS; POPULATION RESEARCH; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SIGNAL TRANSDUCTION; TECHNIQUE;

ANIMALS; CHROMOSOME MAPPING; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EPIDEMIOLOGY, MOLECULAR; GENETIC PREDISPOSITION TO DISEASE; HLA ANTIGENS; HUMANS; MULTIPLE SCLEROSIS; QUANTITATIVE TRAIT LOCI;

EID: 3242715173     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0300-9475.2004.01462.x     Document Type: Review

References (100)

1. Jersild C, Fog T. Histocompatibility (HL-A) antigens associated with multiple sclerosis. Acta Neurol Scand Suppl 1972;51:377.
2. Jersild C, Fog T, Hansen GS, Thomsen M, Svejgaard A, Dupont B. Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet 1973;2:1221-5.
3. Ebers GC, Sadovnick AD, Risch NJ, Group CCS. A genetic basis for familial aggregation in multiple sclerosis. Nature 1995;377:150-1.
4. Sadovnick AD, Ebers GC, Dyment DA et al. Evidence for genetic basis of multiple sclerosis. Lancet 1996;347:1728-30.
5. Wanstrat A, Wakeland E. The genetics of complex autoimmune diseases: non-MHC susceptibility genes. Nat Immunol 2001;2:802-9.
6. Ebers GC, Kukay K, Bulman DE et al. A full genome search in multiple sclerosis. Nat Genet 1996;13:472-6.
7. Haines JL, Ter-Minassian M, Bazyk A et al. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex. Nat Genet 1996;13:469-71.
8. Sawcer S, Jones HB, Feakes R et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat Genet 1996;13:464-8.
9. Kuokkanen S, Gschwend M, Rioux JD et al. Genomewide scan of multiple sclerosis in Finnish multiplex families. Am J Hum Genet 1997;61:1379-87.
10. Olerup O, Hillert J. HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation. Tissue Antigens 1991;38:1-15.
11. The Transatlantic Multiple Sclerosis Genetics Cooperative. A meta-analysis of genomic screens in multiple sclerosis. Mult Scler 2001;7:3-11.
12. Coraddu F, Sawcer S, D'Alfonso S et al. A genome screen for multiple sclerosis in Sardinian multiplex families. Eur J Hum Genet 2001;9:621-6.
13. Broadley S, Sawcer S, D'Alfonso S et al. A genome screen for multiple sclerosis in Italian families. Genes Immun 2001;2:205-10.
14. Akesson E, Oturai A, Berg J et al. A genome-wide screen for linkage in Nordic sib-pairs with multiple sclerosis. Genes Immun 2002;3:279-85.
15. Ban M, Stewart GJ, Bennetts BH et al. A genome screen for linkage in Australian sibling-pairs with multiple sclerosis. Genes Immun 2002;3:464-9.
16. Reboul J, Mertens C, Levillayer F et al. Cytokines in genetic susceptibility to multiple sclerosis: a candidate gene approach. French Multiple Sclerosis Genetics Group. J Neuroimmunol 2000;102:107-12.
17. Seboun E, Oksenberg JR, Rombos A et al. Linkage analysis of candidate myelin genes in familial multiple sclerosis. Neurogenetics 1999;2:155-62.
18. Lock C, Hermans G, Pedotti R et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002;8:500-8.
19. Becanovic K, Wallstrom E, Kornek B et al. New loci regulating rat myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis. J Immunol 2003;170:1062-9.
20. Risch NJ. Searching for genetic determinants in the new millennium. Nature 2000;405:847-56.
21. Oksenberg JR, Baranzini SE, Barcellos LF, Hauser SL. Multiple sclerosis: genomic rewards. J Neuroimmunol 2001;113:171-84.
22. Lassmann H, Bruck W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001;7:115-21.
23. Paterson PY. Transfer of allergic encephalomyelitis in rats by means of lymph node cells. J Exp Med 1960;111:119-36.
24. Ben-Nun A, Wekerle H, Cohen IR. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol 1981;11:195-9.
25. Remlinger P. Contribution à l'étude de la toxine rabique: faits cliniques. C R Soc Biol 1904;56:349.
26. Stuart GaKSK. The neuro-paralytic accidents of anti-rabies treatment. Ann Trop Med Parasitol 1928;22:327-77.
27. Rivers TM, Sprunt DH, Berry GP. Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J Exp Med 1933;58:39-53.
28. Steinman L. Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Neuron 1999;24:511-4.
29. Schwerer B, Lassmann H, Kitz K, Bernheimer H, Wisniewski HM. Fractionation of spinal cord tissue affects its activity to induce chronic relapsing experimental encephalomyelitis. Acta Neuropathol Suppl (Berl) 1981;7:165-8.
30. Zamvil SS, Mitchell DJ, Moore AC, Kitamura K, Steinman L, Rothbard JB. T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature 1986;324:258-60.
31. Tuohy VK, Sobel RA, Lees MB. Myelin proteolipid protein-induced experimental allergic encephalomyelitis. Variations of disease expression in different strains of mice. J Immunol 1988;140:1868-73.
32. Mendel I, Kerlero de Rosbo N, Ben-Nun A. A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells. Eur J Immunol 1995;25:1951-9.
33. Adelmann M, Wood J, Benzel I et al. The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat. J Neuroimmunol 1995;63:17-27.
34. Linington C, Berger T, Perry L et al. T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system. Eur J Immunol 1993;23:1364-72.
35. Weissert R, Svenningsson A, Lobell A, Degraaf KL, Andersson R, Olsson T. Molecular and genetic requirements for preferential recruitment of TCRBV8S2(+) T cells in lewis rat experimental autoimmune encephalomyelitis. J Immunol 1998;160:681-90.
36. Berger T, Weerth S, Kojima K, Linington C, Wekerle H, Lassmann H. Experimental autoimmune encephalomyelitis: the antigen specificity of T lymphocytes determines the topography of lesions in the central and peripheral nervous system. Lab Invest 1997;76:355-64.
37. Linington C, Bradl M, Lassmann H, Brunner C, Vass K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 1988;130:443-54.
38. Amor S, Groome N, Linington C et al. Identification of epitopes of myelin oligodendrocyte glycoprotein for the induction of experimental allergic encephalomyelitis in SJL and Biozzi AB/H mice. J Immunol 1994;153:4349-56.
39. Genain CP, Hauser SL. Allergic encephalomyelitis in common marmosets: pathogenesis of a multiple sclerosis-like lesion. Methods 1996;10:420-34.
40. Lorentzen JC. Identification of arthritogenic adjuvants of self and foreign origin. Scand J Immunol 1999;49:45-50.
41. Storch MK, Stefferl A, Brehm U et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 1998;8:681-94.
42. Gunther E, Odenthal H, Wechsler W. Association between susceptibility to experimental allergic encephalomyelitis and the major histocompatibility system in congenic rat strains. Clin Exp Immunol 1978;32:429-34.
43. Weissert R, Wallstrom E, Storch MK et al. MHC haplotype-dependent regulation of MOG-induced EAE in rats. J Clin Invest 1998;102:1265-73.
44. Weissert R, de Graaf KL, Storch MK et al. MHC class II-regulated central nervous system autoaggression and T cell responses in peripheral lymphoid tissues are dissociated in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis. J Immunol 2001;166:7588-99.
45. Darvasi A. Experimental strategies for the genetic dissection of complex traits in animal models. Nat Genet 1998;18:19-24.
46. Iraqi F, Clapcott SJ, Kumari P, Haley CS, Kemp SJ, Teale AJ. Fine mapping of trypanosomiasis resistance loci in murine advanced intercross lines. Mamm Genome 2000;11:645-8.
47. Wang X, Le Roy I, Nicodeme E et al. Using advanced intercross lines for high-resolution mapping of HDL cholesterol quantitative trait loci. Genome Res 2003;13:1654-64.
48. Mott R, Talbot CJ, Turri MG, Collins AC, Flint J. A method for fine mapping quantitative trait loci in outbred animal stocks. Proc Natl Acad Sci USA 2000;97:12649-54.
49. Xiong M, Guo SW. Fine-scale mapping of quantitative trait loci using historical recombinations. Genetics 1997;145:1201-18.
50. Wakeland E, Morel L, Achey K, Yui M, Longmate J. Speed congenics: a classic technique in the fast lane (relatively speaking). Immunol Today 1997;18:472-7.
51. Sundvall M, Jirholt J, Yang HT et al. Identification of murine loci associated with susceptibility to chronic experimental autoimmune encephalomyelitis. Nat Genet 1995;10:313-7.
52. Baker D, Rosenwasser OA, O'Neil JK, Turk JL. Genetic analysis of experimental allergic encephalomyelitis in mice. J Immunol 1995;155:4046-51.
53. Croxford JL, O'Neill JK, Baker D. Polygenic control of experimental allergic encephalomyelitis in Biozzi ABH and BALB/c mice. J Neuroimmunol 1997;74:205-11.
54. Butterfield RJ, Sudweeks JD, Blankenhorn EP et al. New genetic loci that control susceptibility and symptoms of experimental allergic encephalomyelitis in inbred mice. J Immunol 1998;161:1860-7.
55. Butterfield RJ, Blankenhorn EP, Roper RJ et al. Genetic analysis of disease subtypes and sexual dimorphisms in mouse experimental allergic encephalomyelitis (EAE): relapsing/remitting and monophasic remitting/ nonrelapsing EAE are immunogenetically distinct. J Immunol 1999;162:3096-102.
56. Butterfield RJ, Blankenhorn EP, Roper RJ, Zachary JF, Doerge RW, Teuscher C. Identification of genetic loci controlling the characteristics and severity of brain and spinal cord lesions in experimental allergic encephalomyelitis. Am J Pathol 2000;157:637-45.
57. Encinas JA, Weiner HL, Kuchroo VK. Inheritance of susceptibility to experimental autoimmune encephalomyelitis. J Neurosci Res 1996;45:655-69.
58. Encinas JA, Lees MB, Sobel RA et al. Identification of genetic loci associated with paralysis, inflammation and weight loss in mouse experimental autoimmune encephalomyelitis. Int Immunol 2001;13:257-64.
59. Karlsson J, Zhao X, Lonskaya I, Neptin M, Holmdahl R, Andersson A. Novel quantitative trait loci controlling development of experimental autoimmune encephalomyelitis and proportion of lymphocyte subpopulations. J Immunol 2003;170:1019-26.
60. Dahlman I, Jacobsson L, Glaser A et al. Genome-wide linkage analysis of chronic relapsing experimental autoimmune encephalomyelitis in the rat identifies a major susceptibility locus on chromosome 9. J Immunol 1999;162:2581-8.
61. Roth MP, Viratelle C, Dolbois L et al. A genome-wide search identifies two susceptibility loci for experimental autoimmune encephalomyelitis on rat chromosomes 4 and 10. J Immunol 1999;162:1917-22.
62. Dahlman I, Wallstrom E, Weissert R et al. Linkage analysis of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in the rat identifies a locus controlling demyelination on chromosome 18. Hum Mol Genet 1999;8:2183-90.
63. Bergsteinsdottir K, Yang HT, Pettersson U, Holmdahl R. Evidence for common autoimmune disease genes controlling onset, severity, and chronicity based on experimental models for multiple sclerosis and rheumatoid arthritis. J Immunol 2000;164:1564-8.
64. Jagodic M, Kornek B, Weissert R, Lassmann H, Olsson T, Dahlman I. Congenic mapping confirms a locus on rat chromosome 10 conferring strong protection against myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis. Immunogenetics 2001;53:410-5.
65. Becanovic K. Genetic Regulation of Autoimmune Neuroinflammation. Stockholm: Karolinska institutet, 2003.
66. Encinas JA, Wicker LS, Peterson LB et al. QTL influencing autoimmune diabetes and encephalomyelitis map to a 0.15-cM region containing 112. Nat Genet 1999;21:158-60.
67. + T cells. Eur J Immunol 1995;25:3053-9.
68. Darvasi A, Soller M. Advanced intercross lines, an experimental population for fine genetic mapping. Genetics 1995;141:1199-207.
69. Liu BH. Statistical Genomics. Linkage, Mapping, and QTL Analysis. Boca Raton: CRC Press LLC, 1998.
70. Wang M, Lemon WJ, Liu G et al. Fine mapping and identification of candidate pulmonary adenoma susceptibility 1 genes using advanced intercross lines. Cancer Res 2003;63:3317-24.
71. Chataway J, Feakes R, Coraddu F et al. The genetics of multiple sclerosis: principles, background and updated results of the United Kingdom systematic genome screen. Brain 1998;121:1869-87.
72. Morris C, Luppi M, McDonald M, Barozzi P, Torelli G. Fine mapping of an apparently targeted latent human herpesvirus type 6 integration site in chromosome band 17p13.3. J Med Virol 1999;58:69-75.
73. Challoner PB, Smith KT, Parker JD et al. Plaque-associated expression of humanherpes virus 6 in multiple sclerosis. Proc Natl Acad Sci USA 1995;92:7440-4.
74. Soldan SS, Leist TP, Juhng KN, McFarland HF, Jacobson S. Increased lymphoproliferative response to human herpesvirus type 6A variant in multiple sclerosis patients. Ann Neurol 2000;47:306-13.
75. Swanborg RH, Whittum-Hudson JA, Hudson AP. Infectious agents and multiple sclerosis - are Chlamydia pneumoniae and human herpesvirus 6 involved? J Neuroimmunol 2003;136:1-8.
76. Becker KG, Simon RM, Bailey-Wilson JE et al. Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc Natl Acad Sci USA 1998;95:9979-84.
77. Becanovic K, Backdahl L, Wallstrom E et al. Paradoxical effects of arthritis-regulating chromosome 4 regions on myelin oligodendrocyte glycoprotein-induced encephalomyelitis in congenic rats. Eur J Immunol 2003;33:1907-16.
78. Xu C, Dai Y, Lorentzen JC, Dahlman I, Olsson T, Hillert J. Linkage analysis in multiple sclerosis of chromosomal regions syntenic to experimental autoimmune disease loci. Eur J Hum Genet 2001;9:458-63.
79. Cornelis F, Faure S, Martinez M et al. New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study. Proc Natl Acad Sci USA 1998;95:10746-50.
80. Jawaheer D, Seldin MF, Amos CI et al. A genomewide screen in multiplex rheumatoid arthritis families suggests genetic overlap with other autoimmune diseases. Am J Hum Genet 2001;68:927-36.
81. Olofsson P, Holmberg J, Tordsson J, Lu S, Akerstrom B, Holmdahl R. Positional identification of Ncf1 as a gene that regulates arthritis severity in rats. Nat Genet 2003;33:25-32.
82. Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 2000;51:207-29.
83. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002;2:364-71.
84. van Oosten BW, Barkhof F, Truyen L et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996;47:1531-4.
85. Morel L, Croker BP, Blenman KR et al. Genetic reconstitution of systemic lupus erythematosus immunopathology with polycongenic murine strains. Proc Natl Acad Sci USA 2000;97:6670-5.
86. Morel L, Blenman KR, Croker BP, Wakeland EK. The major murine systemic lupus erythematosus susceptibility locus, Sle1, is a cluster of functionally related genes. Proc Natl Acad Sci USA 2001;98:1787-92.
87. Lander ES, Botstein D. Mapping mendelian factors underlying quantitative traits using RFLP linkage maps. Genetics 1989;121:185-99.
88. Doerge RW. Mapping and analysis of quantitative trait loci in experimental populations. Nat Rev Genet 2002;3:43-52.
89. Jannink JL, Jansen R. Mapping epistatic quantitative trait loci with one-dimensional genome searches. Genetics 2001;157:445-54.
90. Sen S, Churchill GA. A statistical framework for quantitative trait mapping. Genetics 2001;159:371-87.
91. Morel L, Tian XH, Croker BP, Wakeland EK. Epistatic modifiers of autoimmunity in a murine model of lupus nephritis. Immunity 1999;11:131-9.
92. Lambrechts D, Storkebaum E, Morimoto M et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003;34:383-94.
93. Ueda H, Howson JM, Esposito L et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003;423:506-11.
94. Lander E, Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet 1995;11:241-7.
95. Churchill GA, Doerge RW. Empirical threshold values for quantitative trait mapping. Genetics 1994;138:963-71.
96. Dyment DA, Willer CJ, Scott B et al. Genetic susceptibility to MS: a second stage analysis in Canadian MS families. Neurogenetics 2001;3:145-51.
97. Encinas JA, Lees MB, Sobel RA et al. Genetic analysis of susceptibility to experimental autoimmune encephalomyelitis in a cross between SJL/J and B10.S mice. J Immunol 1996;157:2186-92.
98. Dahlman I, Lorentzen JC, de Graaf KL et al. Quantitative trait loci disposing for both experimental arthritis and encephalomyelitis in the DA rat: impact on severity of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis and antibody isotype pattern. Eur J Immunol 1998;28:2188-96.
99. Teuscher C, Butterfield RJ, Ma RLZ, Zachary JF, Doerge RW, Blankenhorn EP. Sequence polymorphisms in the chemokines Scya1 (TCA3), Scya2 (monocyte chemoattractant protein (MCP)-1), and Scya12 (MCP-5) are candidates for eae7, a locus controlling susceptibility to monophasic remitting/nonrelapsing experimental allergic encephalomyelitis. J Immunol 1999;163:2262-6.
100. Blankenhorn EP, Butterfield RJ, Rigby R et al. Genetic analysis of the influence of pertussis toxin on experimental allergic encephalomyelitis susceptibility: an environmental agent can override genetic checkpoints. J Immunol 2000;164:3420-5.